Lisocabtagene Maraleucel Achieves High Response Rate for R/R LBCL

Michael Wang, MD, professor in the Department of Lymphoma & Myeloma at the University of Texas MD Anderson Cancer Center, discusses the FDA approval of lisocabtagene maraleucel.

Michael Wang, MD, professor in the Department of Lymphoma & Myeloma at the University of Texas MD Anderson Cancer Center, discusses the FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi).

According to Wang, the liso-cel clinical trial was in both large B- cell lymphoma and mantle cell lymphoma (MCL). The agent was found to be both effective and tolerable. In patients with relapsed MCL, the overall response rate was 84% and the complete response (CR) rate was 67%. According to Wang, while the 2 trials cannot be compared, this dissimilar to the efficacy seen with brexucabtagene autoleucel (Tecartus).

0:08 | The liso-cel clinical trial were in large-cell lymphoma and mantle cell lymphoma. The large B-cell lymphoma trial has been reported to be very efficacious, and the deciding factor for toxicity is tolerable. During the last ASH meeting, M. Lia Palomba, MD, from Memorial Sloan Kettering Cancer Center, myself, and other colleagues reported the efficacy of liso-cel in relapsed mantle cell lymphoma from 32 patients.

0:43| The overall response rate was 84% with a complete response rate of over 66%. We cannot compare trials across trial, but the efficacy of the brexucabtagene autoleucel can put us into the right context. The overall response rate of was 93% and the CR rate was 67%. So, you can see the CR rates between the 2 products in the 2 separate trials are relatively close. I really think the data on liso-cel relapse in relapsed/refractory mantle cell lymphoma shows good efficacy, and quite has been well-tolerated in relapsed/refractory mantle cell lymphoma.